Search Results - "Thiriaux, J"

Prognostic factors for patients with small cell Lung carcinoma: Analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years by PAESMANS, M, SCULIER, J. P, NINANE, V, KLASTERSKY, J, LECOMTE, J, THIRIAUX, J, LIBERT, P, SERGYSELS, R, BUREAU, G, DABOUIS, G, VAN CUTSEM, O, MOMMEN, P

“…The purposes of this study were to identify prognostic factors for response to chemotherapy, overall survival, and long term survival of patients with small…”
Get full text

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics by SCULIER, J. P, PAESMANS, M, GINER, V, BERCHIER, M. C, MOMMEN, P, NINANE, V, KLASTERSKY, J, LECOMTE, J, VAN CUTSEM, O, LAFITTE, J. J, BERGHMANS, T, KOUMAKIS, G, FLORIN, M. C, THIRIAUX, J, MICHEL, J

“…The European Lung Cancer Working Party (ELCWP) designed a 3-arm phase III randomised trial to determine the role of accelerated chemotherapy in…”
Get full text

A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer by Sculier, J.P, Lafitte, J.J, Berghmans, T, Thiriaux, J, Lecomte, J, Efremidis, A, Ninane, V, Paesmans, M, Mommen, P, Klastersky, J

“…The purpose of the present trial was to determine the activity of gemcitabine as a second-line chemotherapy for non small cell lung cancer (NSCLC). To be…”
Get full text

A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer by Sculier, J. P., Lafitte, J. J., Lecomte, J., Berghmans, T., Thiriaux, J., Florin, M. C., Efremidis, A., Alexopoulos, C. G., Recloux, P., Ninane, V., Mommen, P., Paesmans, M., Klastersky, J.

“…Objective To determine, in stage IV non-small-cell lung cancer (NSCLC), if the combination of gemcitabine—a new active drug—with ifosfamide (IG) or with the…”
Get full text

A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer by Sculier, J.-P., Lafitte, J.-J., Berghmans, T., Van Houtte, P., Lecomte, J., Thiriaux, J., Efremidis, A., Koumakis, G., Giner, V., Richez, M., Corhay, J.-L., Wackenier, P., Lothaire, P., Paesmans, M., Mommen, P., Ninane, V.

“…Purpose: The aim of this study was to determine the role of chemotherapy dose intensity in patients with initially unresectable non-metastatic non-small-cell…”
Get full text

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party by Paesmans, M, Sculier, J.P, Libert, P, Bureau, G, Dabouis, G, Thiriaux, J, Michel, J, Van Cutsem, O, Sergysels, R, Mommen, P, Klastersky, J

“…The aim of this study was the assessment of the predictive value for survival of an antitumoral response to three courses of chemotherapy in association with…”
Get full text

Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy by Berghmans, T., Lafitte, J.J., Thiriaux, J., VanHoutte, P., Lecomte, J., Efremidis, A., Koumakis, G., Giner, V., Richez, M., Corhay, J.L., Wackenier, P., Lothaire, P., Mommen, P., Ninane, V., Sculier, J.P.

“…The 1997 International staging system (ISS) classification separated stage III non-small cell lung cancer (NSCLC) into stages IIIA and IIIB. In a previous…”
Get full text

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861 by Klastersky, J, Sculier, J P, Lacroix, H, Dabouis, G, Bureau, G, Libert, P, Richez, M, Ravez, P, Vandermoten, G, Thiriaux, J

“…The European Organization for Research and Treatment of Cancer (EORTC) Lung Cancer Working Party conducted a randomized trial comparing cisplatin (CDDP; 120…”
Get more information

A phase II randomised trial comparing the cisplatin–etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer by Sculier, J. P., Lafitte, J. J., Lecomte, J., Berghmans, T., Thiriaux, J., Van Cutsem, O., Efremidis, A., Ninane, V., Paesmans, M., Mommen, P., Klastersky, J.

“…Background: A phase II randomised trial was performed with patients with SCLC to determine if the addition of carboplatin to cisplatin–etoposide might improve…”
Get full text

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer by SCULIER, J-P, LAFITTE, J-J, BERGHMANS, T, MOMMEN, P, NINANE, V, KLASTERSKY, J, PAESMANS, M, THIRIAUX, J, ALEXOPOULOS, C. G, BAUMÖHL, J, SCHMERBER, J, KOUMAKIS, G, FLORIN, M. C, ZACHARIAS, C

“…A phase III randomized trial was conducted in patients with metastatic NSCLC, to determine if, in association with mitomycin (6 mg m(-2)) and ifosfamide (3 g…”
Get full text

A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy by Sculier, J. P., Paesmans, M., Lafitte, J. J., Baumöhl, J., Thiriaux, J., van Cutsem, O., Recloux, P., Bureau, G., Berchier, M. C., Zacharias, C., Mommen, P., Bosschaerts, T., Berghmans, T., van Houtte, P., Ninane, V.

“…Purpose: A phase III randomised trial was conducted in patients with non-metastatic unresectable non-small-cell lung cancer in order to compare, in responders…”
Get full text

A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer by Sculier, J.P, Paesmans, M, Thiriaux, J, Lecomte, J, Bureau, G, Giner, V, Koumakis, G, Lafitte, J.J, Berchier, M.C, Alexopoulos, C.G, Zacharias, C, Mommen, P, Ninane, V, Klastersky, J

“…We retrospectively analysed the data obtained in a large randomised trial performed in 505 eligible patients with advanced non-small cell lung cancer. Its…”
Get full text

Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer by Body, J J, Sculier, J P, Raymakers, N, Paesmans, M, Ravez, P, Libert, P, Richez, M, Dabouis, G, Lacroix, H, Bureau, G

“…Carcinoembryonic antigen (CEA) is the only tumor marker of proven, although limited, value for the management of patients with non-small cell lung cancer…”
Get more information

Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy by Sculier, J.P., Paesmans, M., Ninane, V., Giner, V., Bureau, G., Lafitte, J.J., Baumöhl, J., Thiriaux, J., van Cutsem, O., Recloux, P., Berchier, M.C., Zacharias, C., Mommen, P., van Houtte, P., Klastersky, J.

“…PurPose: This study attempted to investigate, in a cohort of patients with clinical stage III initially unresectable non-small cell lung cancer (NSCLC) treated…”
Get full text

The First World Conference on Clinical Cooperative Research for Lung Cancer, Brussels 4–6 March 1999 by Sculier, J.P, Ninane, V, Efremidis, A, Lafitte, J.J, Van Houtte, P, Alexopoulos, C.G, Thiriaux, J, Klastersky, J

Get full text

Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party by Sculier, J P, Paesmans, M, Thiriaux, J, Lecomte, J, Bureau, G, Giner, V, Efremidis, A, Lafitte, J J, Berchier, M C, Alexopoulos, C G, Zacharias, C, Mommen, P, Ninane, V, Klastersky, J

“…A phase III randomized trial in patients with advanced non-small-cell lung cancer (NSCLC) was performed to determine if the addition of ifosfamide to…”
Get more information

Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working Party by Sculier, J P, Bureau, G, Giner, V, Thiriaux, J, Michel, J, Berchier, M C, Van Cutsem, O, Küstner, U, Kroll, F, Mommen, P

“…Prospective trials comparing drug analogues in the treatment of small cell lung cancer are rare. The European Lung Cancer Working Party has conducted a…”
Get more information

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer by Berghmans, Thierry, Scherpereel, Arnaud, Meert, Anne-Pascale, Giner, Vicente, Lecomte, Jacques, Lafitte, Jean-Jacques, Leclercq, Nathalie, Paesmans, Marianne, Sculier, Jean-Paul

“…In a literature meta-analysis, we showed survival benefits for regimens including cisplatin [hazard ratio (HR) 0.61; 95% confidence interval (CI), 0.57-0.66]…”
Get full text

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party by Paesmans, M, Sculier, J P, Libert, P, Bureau, G, Dabouis, G, Thiriaux, J, Michel, J, Van Cutsem, O, Sergysels, R, Mommen, P

“…This study attempted to determine the prognostic value for survival of various pretreatment characteristics in patients with nonresectable non-small-cell lung…”
Get more information

A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer by Klastersky, J, Sculier, J P, Ries, F, Dabouis, G, Libert, P, Schmerber, J, Thiriaux, J, Berchier, M C, Bureau, G, Van Cutsem, O

“…The purpose of this study was to determine the activity of a 4-drug combination chemotherapy: cisplatin, mitomycin C, vindesine and 5-fluorouracil (5-FU) in…”
Get more information